Page 836 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

814 Index

Brain tumor (Continued) Cancer (Continued) Cancer (Continued)
clinical signs of, 658–660, 659f dietary substrate for, 301 stochastic model and, 10–11
surgical resection of, as cure, 164–168, 167f
early diagnosis of, 55
diagnosis of, 660–662
VetBooks.ir biopsy and pathology of, 661–662 enabling characteristics, 48–49 treatment of
all natural cure for, 330
cerebrospinal fluid analysis, 662
genome instability, 49
diagnostic imaging, 660–661, 660f–661f tumor-promoting inflammation, 49 antiangiogenic therapy, 6–7
minimum database, 660 energy metabolism adjustment and, 48 antibody therapy for, 240–241
in dogs, 657–658, 658t epigenetic events and, 10 gene therapy, 251
epidemiology of, 657 etiology of, 1–35 molecular/targeted therapy, 251–285
history of, 658–660 feline immunodeficiency virus and, 93 personalized medicine, 347–348
incidence of, 657 feline leukemia virus and, 23 waste sites and, 92
pathophysiology of, 658–660 gastrointestinal manifestations of Cancer anorexia
prognosis for, 662–665 cancer cachexia and anorexia, 98 effects of, 98, 300–301
treatment of, 662–665 gastrointestinal ulceration, 98–100 evaluation for, 98
chemotherapy, 662–663 genetic basis of, 1 Cancer-associated fibroblast, 51
novel therapeutics, 665 genomic changes and, 40–45 Cancer cachexia
palliative care, 662, 663f genomic dysregulation in, 146–147 effects of, 98, 300–301
radiation therapy, 664–665 growth suppressors, evading, 5–6 evaluation for, 98
surgery, 663–664 hallmarks of, 4, 44f, 45–48 occurrence of, 98
BRCA1/2 mutation, breast cancer and, 605 antigrowth signal, insensitivity to, 46 Cancer-causing virus, 19
Breakpoint cluster region, 148 deregulating cellular energetics, 8–9 Cancer cell
Breast cancer evading growth suppressors, 5–6 destruction of, 255
oncogenic mutations in, 347 genomic instability, 7 evolution of, 51
sex hormones and, 92 proliferative signaling, 4–9 pathways to, 49
BRM. see Biologic-response modifier replicative capacity, 46–47 rescue of, 254
Bromocriptine, for canine pituitary-dependent self-sufficiency of growth signals, 45–46 signaling and, 45–46
hypercortisolism, 567 therapeutic targeting of, 5f Cancer gene, 41
BSA. see Body surface area tumor-promoting inflammation, 7–8 Cancer immunosurveillance, 9
Buffy coat smear, 389 Warburg effect, 8–9 Cancer immunotherapy. see Immunotherapy
Buprenorphine heritable versus sporadic (nonheritable), 1 Cancer metabolism, 300
dose and effects of, 293t–294t imaging modalities for, 113–121 Cancer organ system, parts of, cancer cells and
efficacy of, 295 computed tomography, 115–117 stem cells, 50
Burkitt lymphoma, 26 magnetic resonance image, 117–118 Cancer progenitor, 10–11
Butorphanol, dose and effects of, 293t–294t nuclear scintigraphy, 118 Cancer registry, 82
PET/CT and/or PET/MR, 118–121 cancer incidence/prevalence and cases of,
C radiography, 113 83t
Cabergoline, for canine pituitary-dependent ultrasonography, 113–115 Cancer stem cell (CSC), 10–11
hypercortisolism, 567 immortalization of, 6 colony formation and, 50
Cadherin, 53 immune surveillance of, 231 sites for, 50
Calcium, 100 incidence of, 82–83 spheres of, 11f
Calcium supplementation, for in canines, 82–83 tumor growth/metastasis and, 50
hypoparathyroidism, 581 invasion and metastasis of, 7, 8f Cancer therapy
Calgary-Cambridge Guide, 313 manifestations of, 99b pharmacologic principles in, 188–190
California Animal Neoplasm Registry fever, 107 population pharmacokinetics and, 198
(CANR) hypertrophic osteopathy, 99b, 106–107 response to, 184t
cancer incidence/prevalence and cases of, 83t neutering/spaying and, 92 safety concerns for, 188
goal of, 82–83 nutritional management for, 300 Canine acute myeloid leukemia,
CAM. see Cell adhesion molecule occurrence of myeloproliferative neoplasms, and
Canarypox virus, 240 information sources on, 85 myelodysplasia, 730–739, 730b
Cancer proportional morbidity ratio and, 83 acute myeloid leukemia, 732–734, 733f,
aneuploidy theory of, 6–7 pain level from, 288–289 734t
angiogenesis and, 6–7 paraneoplastic syndromes and, 99b treatment, 738
apoptosis, resisting of, 6 personalized medicine in, 154–155 incidence and risk factors, 730–731
body size and, 3–4, 3f prevalence of myeloproliferative neoplasms, 734–735
cytoplasmic pathways and, 258 in cats, 83 basophilic and eosinophilic leukemia,
definition of, 62 in dogs, 83 735
diagnosis of, 70–74 proportional measures, 83–84 chronic myelogenous leukemia, 734–735
electron microscopy, 74 prevention of, 170–171 essential thrombocythemia, 735
flow cytometry/polymerase chain risk factors for, 85–93, 87t polycythemia vera, 734
reaction, 74 nutritional, 301–302 other bone marrow disorders, 735–739
histochemical stain, 71 risk of, 1–3, 2f diagnostic techniques and workup,
immunohistochemistry, 71–74 signal transduction and, 257 736–738, 737f